To illustrate this, we present data from our own unit (Guy's Hospital), which cover a similar geographical catchment area to St Mary's. The table shows mortality data for the period January 1998 to November 2001, illustrating time of death after arrival of the retrieval team. For the sake of completeness we have also included the four deaths that occurred before the arrival of the team. Over this period we have undertaken 183 retrievals on patients with severe meningococcal disease; 147 (80%) of these required mechanical ventilation and/or inotropic support. 12% of these patients presented with meningitis alone, the remainder with septic shock. The overall crude mortality is 8.2% (15/183), which includes four patients who died before arrival of the retrieval team. Our death rate becomes comparable to that of St Mary's if we exclude patients who die within 6 hours of the retrieval team's arrival, producing a mortality of 4/176 (2.3%).

Our unit policy is one of rapid stabilisation before transfer, as evidenced by a median time spent out of the PICU (the sum of the time spent in the district general hospital and the transit time back to the PICU) of 2 hours 35 minutes. This resulted in only one death in the district general hospital, none during transfer, but a considerable proportion in the early hours following PICU admission.

It is our impression that the St Mary's retrieval process is a considerably longer one, which may artifactually reduce PICU mortality. We would therefore ask that the St Mary's group present their data in a similar manner. Booy and colleagues report a crude mortality of 2% for the year 1997, a figure that has generated considerable media interest. Several reasons are cited for this falling mortality: the provision of mobile intensive care, meticulous attention to stabilising the patient when transferred in the district hospital, and the existence of a specialist “sepsis” intensive care unit. However the way in which the mortality data are presented demonstrate several contradictions. Booy and colleagues purport that intensive care begins from the time the retrieval team is contacted, indeed their own definition? If so, mortality should be adjusted accordingly. Second, has this trend continued in subsequent years? This disease attracts media and public attention par excellence. It is therefore vital that outcome data which are accessible to the public and may be used to influence service reorganisation be presented in a transparent manner.

S M Tibby, I A Murdoch, A Durward
Department of Paediatric Intensive Care, Guy’s Hospital, St Thomas Street, London SE1 9RT, UK;

Correspondence to Dr Tibby; ShaneTibby@gstt.nhs.uk

Table 1 Mortality data for severe meningococcal patients retrieved to Guy’s Hospital January 1998 to November 2001

<table>
<thead>
<tr>
<th>Time to death from PICU team arrival</th>
<th>1998</th>
<th>1999</th>
<th>2000</th>
<th>2001</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deaths prior to team arrival</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Time to death from PICU team arrival</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Less than 6 hours</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>6 to 12 hours</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>12 to 24 hours</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Greater than 24 hours</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Total PICU deaths</td>
<td>5</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Total survivors</td>
<td>40</td>
<td>45</td>
<td>56</td>
<td>31</td>
</tr>
</tbody>
</table>

References

Inter-unit comparisons are flawed
Mortality from meningococcal septic shock may be falling; however, it is difficult to be sure. Inter-unit comparisons of the sort precipitated by these articles and correspondence are inevitably distorted by confounding factors. These factors are not entirely removed by the use of mortality prediction models.

Historically, mortality data for meningococcal septicemia from the UK Public Health Laboratory Service Communicable Disease Surveillance Centre have always shown a lower mortality rate than that for many paediatric intensive care units. However, the comparison is regarded as inappropriate because the surveillance data include patients with positive blood cultures (septicemia) who were not shocked and so would be expected to survive without intensive care. If one admits such patients to intensive care then both crude and standardised mortality are artificially reduced. Furthermore, mortality rates from individual intensive care units or time periods are difficult to compare even using mortality prediction models, without reassurance that the same threshold for admission and/or intervention applies in each case.

The paper by Booy et al contains no reassurances on this issue and no information is given about the performance of the mortality prediction model (PRISM) on their data. Furthermore their series includes cases that appear to exclude the deaths during retrieval. This despite the fact that the quality of retrieval is hailed as a potential cause of decreased mortality. Thorburn et al provide some reassurance by quoting a consistently high rate of ventilation in the reported cases and detailed information on the performance of the mortality prediction model. Hence if there has been a decrease in the threshold for admission it has been accompanied by an increased use of ventilation and perhaps other interventions. It is not clear whether the data from the north west include deaths during retrieval, prior to admission to the PICU.

Both series significantly outperform the expected mortality predicted by PRISM which is not surprising and calls into question the use of the model. Convincing evidence of a fall in mortality for meningococcal septic shock however requires a uniform definition of the illness and “all cause” mortality data from a geographically defined resident population. The regional arrangement for delivery of paediatric intensive care in the north west of England combined with the factors mentioned above make it far more likely that Thorburn et al have indeed detected a true improvement in survival for this condition. Since 1996 there has been a trend for more
children to receive intensive care in lead centres' and this might be expected to reduce mortality across the board. 

G Pearson
Paediatric Intensive Care Unit, Birmingham Children's Hospital, Steelhouse Lane, Birmingham B4 6NH, UK;
Gale.Pearson@Bhamchildrens.wmids.nhs.uk

Improved outcome in severe meningococcal disease

We thank Tibby et al and Pearson for their interest in our paper. We agree with Pearson that evidence for a fall in overall mortality in meningococcal septic shock would require a geographical community based study. We described mortality in severe meningococcal disease in a paediatric intensive care unit (PICU).

We observed a continued decrease in both actual PICU mortality and mortality adjusted for disease severity since the original study period (table 1). Paediatric index of mortality (PIM) is a more contemporary scoring system than PRISM (paediatric risk of mortality score), and so has been calibrated to the more recent decline in PICU mortality rates. PIM gives a score at point of first PICU contact. This general trend of improving meningococcal outcome is also reflected in other PICUs. As shown by the results from St Mary's PICU in London, where in a group with an overall actual mortality of 18.7% (PICU mortality for the study period being 10%), and an additional 8.7% mortality for the “unretrievables”1, they encouragingly had managed to reduce the meningococcal PICU mortality in their “specialist PICU” from 2% to 2% (1992–97).2 Tibby et al, from Guy's Hospital PICU in London (1998–2001), in their letter report a similar very low mortality rate.

There has been continued improvement in outcome from severe meningococcal disease throughout the UK. Early recognition and early institution of treatment are of paramount importance. No single centre holds the monopoly on the improved outcome in meningococcal disease. Although improved intensive care has undoubtedly contributed to this fall in mortality, there should be more recognition of the role of those in the community, parents and carers, general practitioners, and district general hospitals who have significantly contributed (and continue to contribute) to the survival of these critically ill children.

K Thorburn, A Thomson, A Hart
Royal Liverpool Children's Hospital Alder Hey, UK

Mortality in meningococcal disease: please report the figures accurately

We thank Tibby and colleagues for their interest. We believe they and others would be interested in the accompanying figure (see above).

It compares yearly case fatality rates on all referrals to St Mary's PICU, regardless of whether they died before a mobile intensive care team arrived or while the team was assisting with resuscitation. The 29 “outside” deaths are included (3 in 1992/3, 8 in 1994, 10 in 1995, 3 in 1996, 5 in 1997). As stated in our published paper, logistic regression analysis, controlling for disease severity, age and sex, and including these extra deaths, showed no change in the estimated odds ratio for the yearly reduction in death rate, namely 0.41. The overall case fatality rate for 1997 became 6% compared with the PICU admission rate of 2% and a predicted case fatality rate 34% using PRISM scores.

For the 5 deaths in 1997 outside St Mary's PICU, response times between call to the unit and arrival of a team at the DGH varied between 100 and 185 minutes. One child died as the local hospital were telephoning us; two arrested within 90 minutes of St Mary's being called and died within minutes of the team arriving, and the other two died between 2 and 7 hours after arrival.

Genuine reduction in meningococcal deaths results from teamwork

As paediatric intensivists in lead centres accredited for paediatric intensive care (PIC) training and responsible for the care of approximately 7000 cases per year, we read with concern the report from St Mary's Hospital which reported improved outcome of meningococcal disease (MD) in 1997 compared with previous years.

Their reported reduction in mortality must be seen in the context of an overall reduction of childhood mortality of a worldwide and improvement in the outcome for many conditions requiring PIC such as acute respiratory failure,4 persistent pulmonary hypertension5 and complex congenital heart defects.6 Overall UK PIC mortality rates have fallen to a standardised mortality ratio (SMR) of 0.87 as assessed by the Paediatric Index of Mortality7 compared with the model generated in 1994.8 Their application of the severity of illness score (PRISM) is incorrect. No patient has a 100% predicted risk of mortality and therefore all deaths observed in any such study must increase the SMR. The exclusion of nearly half of the total deaths (29/62, 47%) who did not survive the long stabilisation and overall retrieval times must reduce SMR regardless of any other intervention. Whilst inclusion of these cases does not alter the direction of the relationship between SMR and year, it raises the overall mortality in the series towards 20% and more than doubles the headline mortality in 1997. Data from the last 4 years would be of interest. In addition, the lack of any data relating to the performance of the model in different risk groups fails to address the potential confounding factor of disease severity. Since all survivors will reduce SMR, one cause of apparent improvement in risk-adjusted survival is increased admission of low risk cases.

Table 1 Actual mortality, number of patients, mortality per year, and standardised mortality ratio (SMR) in patients admitted to the paediatric intensive care unit (PICU) at the Royal Liverpool Children’s Hospital with meningococcal disease

<table>
<thead>
<tr>
<th>Year</th>
<th>Actual mortality/PICU admissions</th>
<th>Mortality per year</th>
<th>PIM predicted SMR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1992/93</td>
<td>11/123 (8.9%)</td>
<td>4/95 (3%)</td>
<td>1.16</td>
</tr>
<tr>
<td>1994</td>
<td>3/95 (3%)</td>
<td>1.5</td>
<td>0.24</td>
</tr>
<tr>
<td>1995</td>
<td>3/95 (3%)</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td>1996/97</td>
<td>1/95 (1%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

SMR = paediatric index of mortality (PIM) predicted mortality/actual mortality.

References

Figure Actual and predicted annual case fatality rates.


www.archdischild.com
**Reduction in case fatality rate from meningococcal disease is due to genuine teamwork**

We read with disappointment the response of Dr Peters and colleagues1 to our article “Reduction in case fatality rate from meningococcal disease associated with improved healthcare delivery;”2 we agree it is unfortunate that there appears to be a misunderstanding of the message of our study which demonstrated a significant improvement in the mortality of children with meningococcal disease (MD) over a period of time. Contrary to their concerns those results were achieved through genuine teamwork” as stated in our paper. In answer to the specific points they raised: We and other intensivists are also aware that mortality in conditions other than MD is also improving. In our paper we did not state that MD was the only condition in which there is an improvement in mortality. Our paper referred to a study published in Critical Care Medicine which also showed improving survival rates of paediatric patients (with various diseases) over time in another paediatric intensive care (PIC) setting.3

With reference to the patients who died at the referring hospital and their exclusion from the study. Our paper clearly states “Logistic regression analysis, controlling for disease severity, age and sex, showed that over the study period (1992–97) the overall estimate for the reduction in the odds of death was 59% per year (odds ratio for the yearly trend 0.41, 95% CI p=0.000001). This estimate for the reduction in the odds of death was 59% per year (odds ratio for the yearly trend 0.41, 95% CI p=0.000001). This estimate and significance remained the same after inclusion of the 29 deaths that occurred at local hospitals.”

We did not claim that mobile intensive care is the key element in improved survival. What we stated was: “Considerable changes in the management of patients with MD have occurred over the study period. While no single factor alone is likely to explain the reduction in mortality, several factors might have contributed to the improved outcome. In the past, few centres, including those with PICUs, had more than a small number of patients with MD annually. Furthermore, patients were often considered too sick to transfer to a specialist centre and were treated in the A&E department, paediatric ward or adult ICU of the local district general hospital. Establishment of a mobile intensive care team allowed the centralisation of care of children with MD at a specialist clinical and research unit, which in turn enabled extensive experience in the management of MD to be developed; this may be the most important reason for the improved outcome... In other words, it was the increased experience in dealing with meningococcal disease that was the critical factor.”

The role of mobile intensive care was more directly addressed when we stated that it “has probably been another important factor in improved outcome”, not the key factor.

The conclusions of our paper clearly state the multiple factors responsible for the results of the study, which have shown that a notable reduction in the case fatality rate for MD has been achieved.

The purpose of presenting our data was to emphasise the improvements in mortality in a particular group of patients brought about by a change in health care delivery. The key point being early intervention by the multidisciplinary team with a major research interest in the care of the critically ill child with infectious disease, who have the benefit of a “critical mass” experience.

The PICU at St Mary’s Hospital, London was established in 1992, at the time primarily to facilitate the enrolment of children with meningococcal disease into clinical trials. As a large number of critically ill children were referred to our unit, we were unable to record high-quality data regarding clinical status, severity of illness and outcome. We began to demonstrate a reduction in mortality from 1994 onwards, as it takes time to establish the clinical experience which can have a significant impact on the disease process.

The unit at St Mary’s has been greatly involved in the development of a model of care involving “genuine teamwork” with the aim of improving the healthcare of children with MD. To this end we have been working with the meningitis charities which are acknowledged on the paper as bodies who develop guidelines, publish treatment algorithms and improve policies. In addition our research unit has played a key role in the design and implementation of clinical trials of adjunctive treatments in meningococcal disease, which has led to the publication of the only two large randomised, double blind, placebo-controlled studies in childhood septic shock4.

Finally we are humbled by the magnitude of response from many other colleagues who have applauded our efforts. We believe, and have repeatedly stated, that what has been achieved can only be achieved through a multidisciplinary effort involving all sectors of health care delivery.

S Nadel
P Habibi
C de-Munter
J Britto
M Levin
Department of Paediatrics, St Mary’s Hospital, London W2 1NY, UK
Correspondence to: Dr Nadel; s.nadel@ic.ac.uk

R Booy
Department of Child Health, Queen Mary’s School of Medicine and Dentistry, University of London, UK

References


4 Reducing case fatality rate from meningococcal disease: please report the figures accurately. PostScript 561.

References


Weight gain since diagnosis in five infants with ALL, showing peaks and troughs related to intensive treatment blocks.

### References


---

**Why do infants being treated for acute lymphoblastic leukaemia fail to thrive?**

Figure 1 shows the weight gain of five infants with acute lymphoblastic leukaemia (ALL) in relation to centile chart positions, who were treated at the Yorkshire Regional Centre for Paediatric Oncology and Haematology from 1996 until the present. Patients 1–4 were treated in accordance with the MRC UKALL Infant 1 chemotherapy protocol, and patient 5 in accordance with Interfant 99.

The most striking aspect is that from diagnosis to end of intensive therapy (approximately week 40 of treatment), the first four patients, despite aggressive nutritional support, failed to thrive, with two requiring long term total parenteral nutrition (TPN) during maintenance therapy in order to rectify this. Patient 5, in contrast, thrived during treatment.

The infants treated on the MRC UKALL Infant 1 protocol all had grade III/IV gut toxicity following intensive therapy, resulting in the infants being highly catabolic; although some weight gain was achieved with TPN, it was difficult to sustain this increase with enteral feeding.

It became apparent that patients not fully weaned at diagnosis showed a severe delay in feeding skills, becoming orally defensive, resulting in a grossly inadequate solid intake throughout intensive treatment, which continued into maintenance therapy. The only patient to continue normal feeding development was patient 4, who was 36 weeks at diagnosis, and fully weaned.

Patient 5, like the others diagnosed under 30 weeks old, had delayed feeding skills, taking virtually no solids or feed orally. However, she did not show such severe gut toxicity. She was fed an amino acid based formula (Neocate, SHS International Ltd, UK) since induction therapy.

The failure of infants with ALL to thrive may be consequent on severe gut toxicity, length of treatment, and failure of weaning. The improved outcome of patient 5 may be the result of use of a different chemotherapy protocol, which included dexamethasone.

A second possibility is the early introduction of an amino acid based formula, which is a source of l-glutamine, an important nitrogen source for enterocytes, which plays a key role in maintaining mucosal cell integrity and gut barrier function. It may be that exposure to a continuous low dose of glutamine throughout intensive chemotherapy helped to reduce the severity of mucositis.

---

**Osteogenesis imperfecta and intravenous pamidronate**

Osteogenesis imperfecta (OI) is a chronic, disabling condition in which treatment with cyclical intravenous treatment with pamidronate can be useful for symptom relief, despite questions about long term safety. A recent study in this journal showed a decrease in bone turnover and gradual increase in bone density measurements without significant side effects, following such treatment in children affected with OI.

We wish to report our own experience in 10 children with OI who have received cyclical intravenous pamidronate (1 mg/kg/day for three days every three months). The median (range) age at the start of treatment was 9.1 (3.1–12.7) years. Treatment was initiated in the context of symptoms having an adverse effect on the quality of life, associated with evidence of decreased bone density assessed by dual energy x ray absorptiometry (DXA scan, QDR1000/W, Hologic systems, Boston, Massachusetts).

Five of these children were at the severe end of the symptom spectrum (occurring pain, multiple fractures, and impaired mobility). Four children were treated for pain and fractures, whereas one received pamidronate for pain only. After 1.8 (0.9 to 3.0) years of treatment, nine children were pain free. Four children had had no further fractures and one child had improved mobility. The initial infusion of pamidronate was associated with flu like symptoms, fever, rigors, abdominal pain, or vomiting in six children. Serum calcium levels were low (2.2 mmol/l) following therapy in six subjects, and three required treatment with calcium and vitamin D supplements.

Repeat DXA scans showed an increase in lumbar spine bone mineral content (BMC) standard deviation score (SDS) (fig 1), from −3.44 (−6.6 to −1.39) to −0.96 (−3.10 to 3.13) SDS following 1.3 (0.7 to 2.7) years of pamidronate treatment. This beneficial response to treatment was similar to that reported elsewhere.

In conclusion, our findings add to those of others that intravenous pamidronate infusion improves bone mineral density and reduces symptoms of severe pain, recurrent fractures, and impaired mobility in children with OI. There are minor acute side effects to the treatment, but long term safety needs to be determined.

---

**Figure 1**

**Effect of pamidronate on lumbar spine BMC**

![Graph showing effect of pamidronate on lumbar spine BMC](attachment:image.png)

<table>
<thead>
<tr>
<th>Patient</th>
<th>SDS of pamidronate</th>
<th>SDS of sham infusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>−0.96 (−3.10 to 3.13)</td>
<td>−3.44 (−6.6 to −1.39)</td>
</tr>
<tr>
<td>2</td>
<td>−3.44 (−6.6 to −1.39)</td>
<td>−0.96 (−3.10 to 3.13)</td>
</tr>
<tr>
<td>3</td>
<td>−0.96 (−3.10 to 3.13)</td>
<td>−3.44 (−6.6 to −1.39)</td>
</tr>
<tr>
<td>4</td>
<td>−3.44 (−6.6 to −1.39)</td>
<td>−0.96 (−3.10 to 3.13)</td>
</tr>
<tr>
<td>5</td>
<td>−3.44 (−6.6 to −1.39)</td>
<td>−0.96 (−3.10 to 3.13)</td>
</tr>
</tbody>
</table>

---

**Graph Details**

- **X-axis:** Age (in weeks)
- **Y-axis:** Weight gain
- **Legend:**
  - 99th C
  - 50th C
  - 0.4th C
  - Patient 1
  - Patient 2
  - Patient 3
  - Patient 4
  - Patient 5

---

**Table 1**

<table>
<thead>
<tr>
<th>Patient</th>
<th>SDS of pamidronate</th>
<th>SDS of sham infusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>−0.96 (−3.10 to 3.13)</td>
<td>−3.44 (−6.6 to −1.39)</td>
</tr>
<tr>
<td>2</td>
<td>−3.44 (−6.6 to −1.39)</td>
<td>−0.96 (−3.10 to 3.13)</td>
</tr>
<tr>
<td>3</td>
<td>−0.96 (−3.10 to 3.13)</td>
<td>−3.44 (−6.6 to −1.39)</td>
</tr>
<tr>
<td>4</td>
<td>−3.44 (−6.6 to −1.39)</td>
<td>−0.96 (−3.10 to 3.13)</td>
</tr>
<tr>
<td>5</td>
<td>−3.44 (−6.6 to −1.39)</td>
<td>−0.96 (−3.10 to 3.13)</td>
</tr>
</tbody>
</table>
Growth charts for height and weight—statement

The recent review by Professor Noel Cameron was, at least in our view, the most balanced of a number of reports published in recent times. Indeed, one or two of these previously published articles have been wholly misleading, comparing as they did the British 1990 reference with the above, while at the same time failing to mention the introduction of the updated Buckler–Tanner (1995) (Castlemead Reference 11B and 12B) charts still appear to be readily available is indeed a source for concern, as none of the former have been produced or sold for an absolute minimum of 15 years (our sales records go no further back), while the latter has neither been produced or sold for a period of some seven years. In short, Castlemead fully accept that the Tanner Whitehouse Takaishi (1966) and Tanner Whitehouse (1976) (Castlemead Reference 11A and 12A) charts are both out of print and are indeed a source for concern, as none of the former have been produced or sold for an absolute minimum of 15 years (our sales records go no further back), while the latter has neither been produced or sold for a period of some seven years. In short, Castlemead fully accept that the Tanner Whitehouse Takaishi (1966) and Tanner Whitehouse (1976) are long since obsolete, and should play no part in any considerations respecting growth charts for height and weight. Given the above, we are at a loss to understand why these two charts continue to appear as subjects for review.

In an attempt to draw this particular issue to a close, Castlemead is prepared to offer any hospital, department of paediatrics, community health department, or academic institution still holding stocks of either the Tanner Whitehouse Takaishi (1966) or Tanner Whitehouse (1976) (Castlemead Reference 11A and 12A) a “new” for “old” replacement of their stock with the updated Buckler Tanner (1995) growth charts (Castlemead Reference 11B and 12B).

P Wraith
Castlemead Publications, Hartford, UK; peter@castlemeadpublications.com

References


Juvenile dermatomyositis associated with hereditary angioneurotic oedema

Juvenile Dermatomyositis (JDM) is a chronic inflammatory disease probably of an autoimmune nature. 1 Hereditary angioneurotic oedema (HANE) is an enzyme deficiency that results in the loss of inhibition of the classical complement pathway. This results in the consumption of classical pathway factors particularly C4. It is associated with some autoimmune disorders, particularly SLE. We report for the first time the occurrence of JDM in a child with HANE.

A 6 year old Caucasian boy with a family history of type 2 HANE presented with a 4 month history of a red, scaly rash on the back of his fingers and hands, on the dorsum of his feet and toes, on his knees, and above both eyelids. The rash appeared characteristic of JDM. He had difficulty in climbing stairs. Clinical examination revealed some weakness of the proximal muscles. Investigations included a raised creatine kinase of 3000 U/l (normal 50–150), a muscle biopsy typical of JDM, very low levels of C4 and CH50, and confirmation of type 2 HANE with absent functional C1 inhibitor activity but raised immunochromatological levels. Complement C4 returned to normal levels after 2 months treatment with danazol but there was no change in the clinical or laboratory signs of dermatomyositis. Complete resolution of the clinical and biochemical signs of myositis occurred a short time after the introduction of prednisolone. The danazol was stopped but the prednisolone was continued. The reduction in serum complement C4 returned but there has been no clinical deterioration. Subsequently the prednisolone was stopped and there has been no flare of his JDM.

Interestingly the administration of danazol to patients with SLE and HANE has led to the reduction in complement consumption and thus normalisation of C4 levels in the classical pathway accompanied by resolution of the SLE. 2–5 However no such effect was seen in our patient. The failure to alter the course of our patient’s JDM by restoration of the classical pathway components is interesting. It does not suggest that the aetiology of JDM is due to failure of clearance of immune complexes. However, it is possible that the uncontrolled classical pathway activation or acquired C4 deficiency may have contributed to the initiation of the disease.

R Narasimhan, R Lakshman, R S Amos, L H P Williams
Basseread District General Hospital, Worksop, UK
W Egner
Northern General Hospital, Sheffield, UK
A Finn
University of Bristol Medical School, Bristol, UK

Corrections